Sage sues Biogen in wake of $469M buyout provide: report (BIIB:NASDAQ)

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill settlement within the wake of an unsolicited takeover bid valued at round $469M.

The complete lawsuit, which was filed in a Delaware court docket, is sealed. A court docket submitting from Sage (